Sea Mild Biotechnology Co., Ltd. (7516) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Sea Mild Biotechnology Co., Ltd. stock TWD 8.10, price TWD 7.39, upside +9.6%, quality 36 out of 100. Rating: fairly valued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 3.43 TWD – 24.30 TWD · fair‑value band 7.04 TWD – 10.64 TWD · the 7.39 TWD price screens below the 8.10 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Sea Mild Biotechnology Co. in your weekly email
Every Wednesday you see whether Sea Mild Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sea Mild Biotechnology Co., Ltd. manufactures and sells paints, coatings, and detergents in Taiwan. It offers laundry, household, and personal detergent, as well as epidemic prevention products under the Sea Mild Biotech brand name.
Show moreShow less
The company was established in 2007 is headquartered in Taoyuan City, Taiwan.
Stock analysis
Sea Mild Biotechnology Co., Ltd. (7516) currently trades at 7.39 TWD, while our model-based Fair Value estimate is 8.10 TWD, so the stock looks roughly fairly valued today (gap 8.8%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 10.11 TWD per share, and 8 of the 15 models we run sit above the 7.39 TWD price.
Bear case: the Asset-Based group reads lowest at 2.21 TWD, and 7 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: 7.04 TWD (bear) to 10.64 TWD (bull), the price of 7.39 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sea Mild Biotechnology Co., Ltd. reported revenue of 342M TWD in FY2025 versus 164M TWD in FY2021, a compound +20.2%/yr. Reported net income was 8.8M TWD in FY2025.
Key figures
Market cap 147M TWD (≈ $4.5M) Micro · P/E ratio 21.1 · P/S ratio 0.40 · EPS (TTM) 0.3500 TWD · Net margin 1.8% · Return on equity 6.0% · Return on assets (EBIT) −2.6% (5-year average) · Operating margin 0.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at 10%, 7516 screens cheaper than that median.
Fair Value models
Bear7.04 TWDFair Value 8.10 TWDBull10.64 TWD
Price 7.39 TWD · Upside +9.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.3001 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−18% → 2%
Compare Sea Mild Biotechnology Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside+9.6% · Above median
Profitability
Return on equity (12 months)6.0% · Below median
Return on assets2.7% · Below median
Net margin (12 months)1.8% · Below median
Operating margin (12 months)0.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)18.4% · Top 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sea Mild Biotechnology Co., Ltd. (7516) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 8.10 TWD versus a price of 7.39 TWD, about +10% upside (fairly valued).
What is the fair value of 7516?
Our model-based fair value for Sea Mild Biotechnology Co., Ltd. is 8.10 TWD (as of Nov 7, 2026), built from audited fundamentals. The current price: 7.39 TWD.
What is the quality score of 7516?
Sea Mild Biotechnology Co., Ltd. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sea Mild Biotechnology Co., Ltd. (7516)?
Our model-based price target is the fair value of 8.10 TWD (as of Nov 7, 2026) from 15 valuation models. Cautious scenario 7.04 TWD, optimistic scenario 10.64 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Sea Mild Biotechnology Co., Ltd. stock forecast for 2026?
Our models put fair value at 8.10 TWD, about +10% upside versus a price of 7.39 TWD (fairly valued). Cautious scenario 7.04 TWD, optimistic scenario 10.64 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Sea Mild Biotechnology Co., Ltd. (7516)?
Sea Mild Biotechnology Co., Ltd. reported trailing-twelve-month revenue of about 372M TWD (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Sea Mild Biotechnology Co., Ltd. (7516)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sea Mild Biotechnology Co., Ltd. it is 8.10 TWD per share (as of Nov 7, 2026), against a price of 7.39 TWD. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Sea Mild Biotechnology Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 7516 trades below its calculated fair value: price 7.39 TWD, fair value 8.10 TWD, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7516?
No. The price is what the market pays today (7.39 TWD); the fair value is what the company's own numbers justify (8.10 TWD). For Sea Mild Biotechnology Co., Ltd. the two are 0.7100 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Sea Mild Biotechnology Co., Ltd. worth?
The market values Sea Mild Biotechnology Co., Ltd. at about 147M TWD (market capitalisation, as of Nov 7, 2026). Per share that is 7.39 TWD; our models calculate a fair value of 8.10 TWD per share.
What do the bullish and bearish scenarios say about 7516?
Our models span a range for Sea Mild Biotechnology Co., Ltd.: cautious scenario 7.04 TWD, base 8.10 TWD, optimistic 10.64 TWD per share (as of Nov 7, 2026, price 7.39 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7516?
Sea Mild Biotechnology Co., Ltd. trades at a price-to-earnings ratio of 21.1 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8.10 TWD is built from several models across several years. Other multiples: P/B 1.3, P/S 0.4, EV/EBITDA 5.9.
How solid is the balance sheet of Sea Mild Biotechnology Co., Ltd. (7516)?
Balance-sheet figures for Sea Mild Biotechnology Co., Ltd. (as of Nov 7, 2026): return on equity 6.0%, debt of 0.12 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 7516 from its 52-week high?
Sea Mild Biotechnology Co., Ltd. trades at 7.39 TWD, about 44% below its 52-week high of 13.10 TWD and at the low of 7.39 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 8.10 TWD is for.
Which stocks are comparable to Sea Mild Biotechnology Co., Ltd.?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sea Mild Biotechnology Co., Ltd. stock attractive at the current price?
The data as of Nov 7, 2026: price 7.39 TWD, calculated fair value 8.10 TWD (+10%), Quality Score 36/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7516 calculated?
We run Sea Mild Biotechnology Co., Ltd. through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8.10 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sea Mild Biotechnology Co., Ltd. currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sea Mild Biotechnology Co., Ltd. (7516)?
The closing price on Nov 6, 2026 was 7.39 TWD. Our model-based fair value is 8.10 TWD, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sea Mild Biotechnology Co., Ltd. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Sea Mild Biotechnology Co., Ltd.
How large is the market capitalisation of Sea Mild Biotechnology Co., Ltd. (7516)?
The market capitalisation of Sea Mild Biotechnology Co., Ltd. is 147M TWD (≈ $4.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sea Mild Biotechnology Co., Ltd. (7516)?
The price-to-sales ratio of Sea Mild Biotechnology Co., Ltd. is 0.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sea Mild Biotechnology Co., Ltd. (7516)?
Earnings per share at Sea Mild Biotechnology Co., Ltd. are 0.3500 TWD (price ÷ EPS = P/E 21.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sea Mild Biotechnology Co., Ltd. (7516)?
The net margin of Sea Mild Biotechnology Co., Ltd. is 1.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sea Mild Biotechnology Co., Ltd. (7516)?
The return on equity (ROE) of Sea Mild Biotechnology Co., Ltd. is 6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sea Mild Biotechnology Co., Ltd. (7516)?
On an EBIT basis the return on assets of Sea Mild Biotechnology Co., Ltd. is −2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sea Mild Biotechnology Co., Ltd. (7516)?
The operating margin of Sea Mild Biotechnology Co., Ltd. is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sea Mild Biotechnology Co., Ltd. (7516)?
Revenue at Sea Mild Biotechnology Co., Ltd. is growing +18.4% versus a year earlier (3y avg +19.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sea Mild Biotechnology Co., Ltd. (7516)?
Earnings per share at Sea Mild Biotechnology Co., Ltd. are growing −42.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sea Mild Biotechnology Co., Ltd. (7516) generate?
The free cash flow of Sea Mild Biotechnology Co., Ltd. is −7.4M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sea Mild Biotechnology Co., Ltd. (7516) hold?
Sea Mild Biotechnology Co., Ltd. holds more cash than debt, 13.0M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sea Mild Biotechnology Co., Ltd. in the live analysis
One click puts Sea Mild Biotechnology Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026